Basic information Safety Related Supplier

ChemicalBook Product Catalog Samuraciclib hydrochloride

1/1

Samuraciclib hydrochloride NEW

$116.00 1mg

$247.00 5mg

$373.00 10mg

Min. Order
Purity99.80%
Cas No1805789-54-1
Supply Ability10g
Update time2026-04-13

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

VIP6Y

United States

United States

show more

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Trade Company

Chemical Properties

Product Name	Samuraciclib hydrochloride
CAS No	1805789-54-1
EC-No
Min. Order
Purity	99.80%
Supply Ability	10g
Release date	2026/04/13

Product Introduction

Bioactivity

Name	Samuraciclib hydrochloride
Description	Samuraciclib hydrochloride (ICEC0942 hydrochloride) is a potent, selective, ATP competitive and oral active CDK7 inhibitor with IC50 of 41 nM. The selectivity of Samuraciclib hydrochloride is 45-, 15-, 230- and 30-fold higher than CDK1, CDK2 (IC50 is 578 nM), CDK5 and CDK9 respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib hydrochloride has anti-tumor effects.
In vitro	Samuraciclib (ICEC0942; 0-10 μM; 24 hours; HCT116 cells) treatment can promote apoptosis. Samuraciclib (ICEC0942; 0-10 μM; 24 hours; HCT116 cells) treatment can induce cell cycle arrest. Samuraciclib (ICEC0942; 0-10 μM; 0-24 hours; HCT116 cells) treatment inhibited the phosphorylation of PolII CTD in HCT116 colon cancer cells in a dose- and time-dependent manner. ICEC0942 also inhibits the phosphorylation of CDK1, CDK2 and retinoblastoma. Samuraciclib (ICEC0942) inhibits the growth of MCF7, T47D, MDA-MB-231, HS578T, MDA-MB-468, MCF10A and HMEC cells with GI50 values of 0.18 μM, 0.32 μM, 0.33 μM, 0.21 μM, 0.22 μM It is 0.67 μM and 1.25 μM.
In vivo	Samuraciclib (ICEC0942; 100 mg / kg; oral tube; daily; 14 consecutive days; female nu / nu-BALB / c athymic nude mice) treatment inhibited tumor growth by 60% on day 14 with a significant reduction in PolII Ser2 and Ser5 phosphorylation in PBMC and tumors. The combination of Samuraciclib (ICEC0942) and ICI 47699 treatment showed complete stagnation of estrogen receptor (ER) positive tumor xenografts.
Storage	Store at low temperature,Keep away from moisture \| Shipping with blue ice/Shipping at ambient temperature.
Solubility Information	H2O : 55 mg/mL (127.62 mM), Sonication is recommended. DMSO : 150 mg/mL (348.05 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.64 mM), Sonication is recommended.
Keywords	Samuraciclib hydrochloride \| Samuraciclib \| PolII \| phosphorylates \| non-covalent \| Inhibitor \| inhibit \| ICEC-0942 Hydrochloride \| ICEC0942 Hydrochloride \| ICEC-0942 \| ICEC0942 \| ICEC 0942 Hydrochloride \| ICEC 0942 \| deregulation \| Cyclin dependent kinase \| cycle \| CT-7001 Hydrochloride \| CT7001 Hydrochloride \| CT-7001 \| CT7001 \| CT 7001 Hydrochloride \| CT 7001 \| CDK9/CycT1 \| CDK7/cyclinH \| CDK7/cyclin H \| CDK7 \| CDK6/cycD1 \| CDK5/p35NCK \| CDK4/Cyc D1 \| CDK2/cyclinA \| cdk2/cyclin A \| CDK1/cyc A \| CDK \| ATP-competitive \| Asp155 \| arrest \| Apoptosis \| anti-tumor
Inhibitors Related	Stavudine \| Aceglutamide \| Urea \| Tamoxifen \| Cysteamine hydrochloride \| Metronidazole \| Citric Acid Triammonium \| Formamide \| Dimethyl phthalate \| Alginic acid \| Sodium Molybdate \| Sildenafil citrate
Related Compound Libraries	Highly Selective Inhibitor Library \| Anti-Pancreatic Cancer Compound Library \| Bioactive Compound Library \| Kinase Inhibitor Library \| Anti-Cancer Clinical Compound Library \| Drug Repurposing Compound Library \| Inhibitor Library \| Anti-Aging Compound Library \| Bioactive Compounds Library Max \| Cell Cycle Compound Library \| Anti-Cancer Drug Library \| Anti-Cancer Active Compound Library

show more

Company Profile Introduction

You may like

Recommended supplier

Send Inquriy